Mammographic breast density response to aromatase inhibition.

CONCLUSIONS: In postmenopausal women treated with aromatase inhibitors, 14% of cases had a MBD reduction of more than 5%, but these decreases did not differ from matched controls. These data suggest that MBD is not a clinically useful biomarker for predicting the value of aromatase inhibitor therapy in White postmenopausal women. Clin Cancer Res; 19(8); 2144-53. ©2013 AACR.
PMID: 23468058 [PubMed - in process]

Source: Clinical Breast Cancer - April 15, 2013 Category: Cancer & Oncology Authors: Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN Tags: Clin Cancer Res Source Type: research